<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00868842</url>
  </required_header>
  <id_info>
    <org_study_id>HM10870</org_study_id>
    <secondary_id>AADCRC-VCU-01</secondary_id>
    <nct_id>NCT00868842</nct_id>
  </id_info>
  <brief_title>Desensitization of Human Mast Cells: Mechanisms and Potential Utility for Preventing Anaphylaxis</brief_title>
  <official_title>Open-label, Single-center Study of Whether Oral Penicillin Desensitization of Healthy Sensitive Subjects Results in Allergen Cross-desensitization of Mast Cells by Skin Testing and Desensitization of Peripheral Blood Basophils.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single-center study of whether oral penicillin desensitization of&#xD;
      healthy sensitive subjects results in allergen cross-desensitization of mast cells by skin&#xD;
      testing and desensitization of peripheral blood basophils. The primary endpoint(s) will be&#xD;
      PC3 prick skin test values to penicillin, aeroallergen(s) and codeine. Secondary endpoints&#xD;
      will be levels of Syk in purified basophils determined by flow cytometry (mean fluorescence&#xD;
      intensity) and basophil degranulation (% tryptase release) to anti-Fc√•RI and to calcium&#xD;
      ionophore.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Decreased skin test sensitivity to Pre-pen (PC3 value)</measure>
    <time_frame>June 2012</time_frame>
  </primary_outcome>
  <enrollment type="Actual">10</enrollment>
  <condition>Anaphylaxis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Clinical and community recruitment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent obtained.&#xD;
&#xD;
          -  Male, or non-pregnant female, 18-45 years of age who are in good health.&#xD;
&#xD;
          -  Clinical history of a penicillin allergy consisting of an immediate hyper- sensitivity&#xD;
             reaction such as anaphylaxis, urticaria/angioedema or broncho- spasm, and a positive&#xD;
             skin prick test to penicillin G.&#xD;
&#xD;
          -  Positive skin test to at least one aeroallergen to indicate sensitivity, but clinical&#xD;
             disease (allergic rhinitis) is not necessary.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dermatographism or severe dermatologic condition, such as advanced eczema or&#xD;
             psoriasis, that will not allow an adequate uninvolved area for skin testing.&#xD;
&#xD;
          -  Negative skin tests to penicillin G or to all aeroallergens test.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Antihistamine medications taken within one week of testing; systemic steroids,&#xD;
             B-blockers or ACE -inhibitors taken over the previous month; omalizumab therapy at any&#xD;
             time; those receiving or who have received immunotherapy; and those who have been&#xD;
             desensitized to any drug within 6 months.&#xD;
&#xD;
          -  Allergic reaction to a B-lactam antibiotic within 1 month.&#xD;
&#xD;
          -  Current asthma; significant pulmonary, cardiovascular, renal, hepatobiliary or&#xD;
             neurological diseases, or another disease process that the investigator feel would put&#xD;
             the subject at risk of an adverse event.&#xD;
&#xD;
          -  Mental illness or history of drug or alcohol abuse that, in the opinion of the&#xD;
             investigator, would interfere with the participant's ability to comply with study&#xD;
             requirements.&#xD;
&#xD;
          -  Inability or unwillingness of a participant to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lawrence B. Schwartz, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <study_first_submitted>March 23, 2009</study_first_submitted>
  <study_first_submitted_qc>March 24, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2009</study_first_posted>
  <last_update_submitted>April 10, 2014</last_update_submitted>
  <last_update_submitted_qc>April 10, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Penicillin</keyword>
  <keyword>Allergy</keyword>
  <keyword>Prevention</keyword>
  <keyword>Anaphylaxis</keyword>
  <keyword>Clinically proven history of penicillin allergy</keyword>
  <keyword>preventing anaphylaxis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anaphylaxis</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

